Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Y Camp

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Immunity|November 1, 2025
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaKevin Bi, Soki Kashima, Sabrina Y Camp, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinomaPrathyusha Konda, Cary N Weiss, Yantong Cui, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticityErica M Pimenta, Amanda E Garza, Sabrina Y Camp, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancerSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
Science Advances|February 20, 2026
Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and <i>BAP1</i> lossSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
Science Translational Medicine|January 21, 2026
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticityErica M Pimenta, Amanda E Garza, Sabrina Y Camp, et al.
Cell Genomics|September 30, 2022
A patient-driven clinicogenomic partnership for metastatic prostate cancerJett Crowdis, Sara Balch, Lauren Sterlin, et al.
Nature Medicine|March 5, 2021
Transcriptional mediators of treatment resistance in lethal prostate cancerMeng Xiao He, Michael S Cuoco, Jett Crowdis, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Immunity|November 1, 2025
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaKevin Bi, Soki Kashima, Sabrina Y Camp, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinomaPrathyusha Konda, Cary N Weiss, Yantong Cui, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticityErica M Pimenta, Amanda E Garza, Sabrina Y Camp, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancerSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
Science Advances|February 20, 2026
Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and <i>BAP1</i> lossSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
Science Translational Medicine|January 21, 2026
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticityErica M Pimenta, Amanda E Garza, Sabrina Y Camp, et al.
Cell Genomics|September 30, 2022
A patient-driven clinicogenomic partnership for metastatic prostate cancerJett Crowdis, Sara Balch, Lauren Sterlin, et al.
Nature Medicine|March 5, 2021
Transcriptional mediators of treatment resistance in lethal prostate cancerMeng Xiao He, Michael S Cuoco, Jett Crowdis, et al.
Pageof 3